The Role of Some Chemokines from the CXC Subfamily in a Mouse Model of Diabetic Neuropathy

Figure 6

Effects of CXCL1, CXCL5, CXCL9, or CXCL12 administration on thermal hyperalgesia. The influence of a single intrathecal administration of 10 ng, 100 ng, or 500 ng/5 μL of CXCL1 (a), CXCL5 (b), CXCL9 (c), or CXCL12 (d) on thermal hyperalgesia was evaluated using the cold plate test. The measurements were taken 1, 4, and 24 hours after chemokine administration. The data are presented as fold change in the control (naïve) ± S.E.M. (6–16 mice per group). Intergroup differences were analyzed by an ANOVA and Bonferroni’s Multiple Comparison Test. , , and indicate a significant difference; the statistical analysis was performed versus control (naïve) mice.

(a)

(b)

(c)

(d)